Clinical Oncology, Journal Year: 2025, Volume and Issue: 41, P. 103793 - 103793
Published: Feb. 25, 2025
Language: Английский
Nature reviews. Cancer, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 14, 2025
Language: Английский
Citations
2
Sensors and Actuators B Chemical, Journal Year: 2024, Volume and Issue: 405, P. 135291 - 135291
Published: Jan. 6, 2024
Language: Английский
Citations
14
Biomolecules, Journal Year: 2024, Volume and Issue: 14(2), P. 184 - 184
Published: Feb. 3, 2024
Tumor diseases become a huge problem when they embark on path that advances to malignancy, such as the process of metastasis. Cancer metastasis has been thoroughly investigated from biological perspective in past, whereas it still less explored physical perspective. Until now, intraluminal pathway cancer received most attention, while interaction cells with macrophages little attention. Apart biochemical characteristics, tumor treatments also rely microenvironment, which is recognized be immunosuppressive and, recently found, mechanically stimulates and thus alters their functions. The review article highlights other vascular metastatic route discusses impact this intercellular interplay mechanical characteristics subsequently functionality cells. For instance, can guide intravascular metastasis, whereby help circumvent adverse conditions within blood or lymphatic vessels. Macrophages induce microchannel tunneling possibly avoid forces during extra- intravasation reduce lumen due flow. key players traditional route. Moreover, effects flows are presented, influences, characterized. Finally, increased knowledge opens up new perspectives for treatment.
Language: Английский
Citations
11
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 4, 2024
Receptor tyrosine kinases (RTKs) play a crucial role in cellular signaling and oncogenic progression. Epidermal growth factor receptor kinase inhibitors (EGFR TKIs) have become the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations, but resistance frequently emerges between 10 to 14 months. A significant this is of human EGFR 3 (HER3), an family member. Despite its significance, effective targeting HER3 still developing. This review aims bridge gap by deeply examining HER3’s pivotal contribution TKI spotlighting emerging HER3-centered therapeutic avenues, including monoclonal antibodies (mAbs), TKIs, antibody-drug conjugates (ADCs). Preliminary results indicate combining HER3-specific treatments TKIs enhances antitumor effects, leading increased objective response rate (ORR) prolonged overall survival (OS) resistant cases. Embracing HER3-targeting therapies represents transformative approach against emphasizes importance further research optimize patient stratification understand mechanisms.
Language: Английский
Citations
10
Developmental Cell, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
1
Molecular Biology of the Cell, Journal Year: 2025, Volume and Issue: 36(2)
Published: Jan. 28, 2025
The cellular electrical signals of living organisms were discovered more than a century ago and have been extensively investigated in the neuromuscular system. Neuronal depolarization hyperpolarization are essential for our physiological pathological functions. Bioelectricity is being recognized as an ancient, intrinsic, fundamental property all cells, it not limited to Instead, emerging evidence supports view bioelectricity instructional signaling cue physiology, embryonic development, regeneration, human diseases, including cancers. Here, we highlight current understanding share views on challenges perspectives.
Language: Английский
Citations
1
Cancers, Journal Year: 2024, Volume and Issue: 16(10), P. 1808 - 1808
Published: May 9, 2024
Pancreatic cancer is the sixth leading cause of cancer-related mortality globally. As most common form pancreatic cancer, ductal adenocarcinoma (PDAC) represents up to 95% all cases, accounting for more than 300,000 deaths annually. Due lack early diagnoses and high refractory response currently available treatments, PDAC has a very poor prognosis, with 5-year overall survival rate less 10%. Targeted therapy immunotherapy are highly effective have been used treatment many types cancer; however, they offer limited benefits in patients due tumor-intrinsic extrinsic factors that culminate drug resistance. The identification key responsible growth resistance different treatments valuable developing new therapeutic strategies. In this review, we discuss some molecules which promote initiation progression, their potential as targets treatment. We also evaluate challenges associated patient outcomes clinical trials implications future research.
Language: Английский
Citations
8
Briefings in Bioinformatics, Journal Year: 2023, Volume and Issue: 25(2)
Published: Dec. 19, 2023
Abstract The vast amount of available sequencing data allows the scientific community to explore different genetic alterations that may drive cancer or favor progression. Software developers have proposed a myriad predictive tools, allowing researchers and clinicians compare prioritize driver genes mutations their relative pathogenicity. However, there is little consensus on computational approach golden standard for comparison. Hence, benchmarking tools depends highly input data, indicating overfitting still massive problem. One solutions limit scope usage specific tools. such limitations force walk tightrope between creating using high-quality purpose describing complex driving cancer. While knowledge development increases daily, many bioinformatic pipelines rely single nucleotide variants in vacuum without accounting cellular compartments, mutational burden disease Even within bioinformatics biology, research fields work silos, risking overlooking potential synergies breakthroughs. Here, we provide an overview databases datasets building testing Furthermore, introduce genes, mutations, impact these based structural analysis. Additionally, suggest recommend directions field avoid silo-research, moving towards integrative frameworks.
Language: Английский
Citations
13
International Journal of Cancer, Journal Year: 2024, Volume and Issue: 155(2), P. 324 - 338
Published: March 27, 2024
Abstract Breast cancer has become the most commonly diagnosed cancer. The intra‐ and interpatient heterogeneity induced a considerable variation in treatment efficacy. There is an urgent requirement for preclinical models to anticipate effectiveness of individualized drug responses. Patient‐derived organoids (PDOs) can accurately recapitulate architecture biological characteristics origin tumor, making them promising model that overtake many limitations cell lines PDXs. However, it still unclear whether PDOs‐based testing benefit breast patients, particularly those with tumor recurrence or resistance. Fresh samples were surgically resected organoid culture. Primary PDOs subsequently subjected H&E staining, immunohistochemical (IHC) analysis, whole‐exome sequencing (WES) make comparisons. Drug sensitivity tests performed evaluate feasibility this predicting patient response clinical practice. We established 75 patient‐derived models. results IHC, WES revealed inherited histologic genetic their parental tissues. successfully predicted patient's response, cases exhibited consistency between PDOs' susceptibility test matched patient. conclude platform be potential tool used selection effective drugs guided personalized therapies patients advanced
Language: Английский
Citations
5
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1870(7), P. 167260 - 167260
Published: May 21, 2024
Language: Английский
Citations
5